Manchester Capital Management’s Abivax ABVX Stock Holding History

Manchester Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.7K	Hold	200	–	–	﹤0.01%	640
2026 Q1	$22.3K	Buy	+200	New	+$23.7K	﹤0.01%	655

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Manchester Capital Management's ABVX Position: Q2 2026 in Review

Manchester Capital Management held its Abivax (ABVX) position steady in Q2 2026 at 200 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Manchester Capital Management first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Manchester Capital Management held 200 shares of Abivax worth $26.7K as of Q2 2026.
Manchester Capital Management left its Abivax share count unchanged in Q2 2026.
Abivax made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #640 holding.
Manchester Capital Management first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.